Oral News and Research

RSS

Aspen Dental to inaugurate new office in Davenport, Iowa

Patients looking for a dentist in Davenport, Iowa now have a new dental care provider option with the opening of a new Aspen Dental office this month. The new practice, which opens on July 28 at 5270 Elmore Avenue, will provide dental services that range from dentures and preventive care to general dentistry and restoration.

25 Jul 2011

Fluoride at recommended levels is both safe and effective for reducing decay and tooth loss

Tooth decay remains a health care problem that touches people of all ages. Many communities could benefit greatly and reduce tooth decay significantly by implementing nature's cavity fighter, fluoride.

22 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

Abbott's AACC workshops to showcase HIV and vitamin D diagnostics, lab informatics

Abbott announced its schedule of key workshops and scientific presentations at the American Association for Clinical Chemistry (AACC) annual meeting, July 24-28 in Atlanta.

22 Jul 2011

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama.

22 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

FDA approves Boca Pharmacal's Hydrocodone Bitartrate and Acetaminophen Oral Solution ANDA

Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5mg / 325mg per 5mL, the generic version of Hycet Oral Solution distributed by FSC Laboratories, Inc.

22 Jul 2011

Taller women more prone to cancer: Study

New research has shown that taller women could be more prone to suffering from cancer. The British study published online in the medical journal The Lancet on Thursday said cancer risk rose about 16% for every 4-inch rise in height. Increasing height heightened the chances of cancers of breast, ovary, womb, bowel, leukemia and malignant melanoma (skin cancer) the study found.

21 Jul 2011

Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.

21 Jul 2011

Senate Commission compiles new threshold limit values for dusts

The 2011 MAK and BAT Values List compiled by the Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, a Senate Commission of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), recommends reducing the general threshold limit value for dust for the alveolar fraction in light of recent studies and classifies such dusts as carcinogenic when these thresholds are exceeded.

21 Jul 2011

Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's

Bristol-Myers Squibb Company today announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer's disease.

21 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

VIVUS to present topiramate exposure, birth defect data at IEC

VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.

20 Jul 2011

Kool Smiles inaugurates new Elkhart office to offer dental services

Kool Smiles, a leading dental health provider for children and adults, has opened a new office in Elkhart. Kool Smiles of Elkhart, which began seeing patients on July 11, puts quality dental care within reach of even more previously underserved area residents.

20 Jul 2011

Medco announces new offerings within Advanced Oncology Solutions

Medco Health Solutions, Inc. today announced new offerings within its Advanced Oncology Solutions, that include treatment pathways decision support with embedded pharmacogenomic testing and nutrition recommendations for cancer patients.

20 Jul 2011

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Bristol-Myers Squibb Company and AstraZeneca today reported the outcome of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.

20 Jul 2011